Asceneuron

Biotech & Life Sciences · Lausanne, Switzerland · Founded 2012

Asceneuron is an emerging biotech company focused on discovering and developing groundbreaking therapeutics for neurodegenerative disorders, particularly those with high unmet medical needs such as orphan tauopathies and other related diseases. The company operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from central nervous system (CNS) disorders. Asceneuron's business model revolves around research and development (R&D) of innovative small molecules that have the potential to halt and prevent neurodegeneration. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products. Asceneuron's R&D pipeline is designed to address significant gaps in current treatment options, aiming to improve patients' lives by providing effective solutions for complex brain diseases. The company actively participates in industry conferences and collaborates with leading experts to stay at the forefront of CNS therapeutic development. Keywords: neurodegenerative, therapeutics, CNS disorders, tauopathies, biotech, small molecules, R&D, brain diseases, innovative, partnerships.

Valuation $100–500M

Revenue $1–10M

Headcount <100

Total funding $100–500M

Unlock exact values

Investors

10 investors on Asceneuron's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 1 investor entered at this stage

Michael J. Fox Foundation for Parkinson's Research

Series A 5 investors entered at this stage

Kurma Partners

Sofinnova Partners

SR One

M Ventures

Johnson & Johnson Innovation

Series B+ 4 investors entered at this stage

Novo Holdings

EQT Life Sciences

GSK

OrbiMed

Global footprint

Where Asceneuron has talent and traffic

Workforce by country

4 countries with
team presence

🇨🇭 Switzerland55.6%

🇺🇸 United States22.2%

🇳🇱 Netherlands11.1%

🇬🇧 United Kingdom11.1%

4 countries shown

Talent graph

The shape of Asceneuron's talent

Dealroom maps Asceneuron's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

10 team members profilednamed & role-tagged by Dealroom

9 employeestotal headcount

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Asceneuron's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Asceneuron

An AI-synthesized read of the highest-engagement posts about Asceneuron on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Asceneuron on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles